Trevi Therapeutics, Inc. (TRVI)

Travelers Companies (TRV) has introduced TravelersLLM, a proprietary large language model built on millions of internal documents to support its property and casualty insurance operations and its broader artificial intelligence ecosystem. See our latest analysis for Travelers Companies.

See the latest Trevi Therapeutics Inc stock price (TRVI:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

Institutional investors own 95.76% of the company’s stock. Shares of NASDAQ:TRVI opened at $17.93 on Friday. The company has a market capitalization of $2.55 billion, a PE ratio of -56.03 and a beta of 1.00. Trevi Therapeutics, Inc. has a 12-month low of $5.71 and a 12-month high of $19.26. The busi…

Looking to buy Trevi Therapeutics Inc Stock? Get the latest TRVI quote, news, earnings, forecast, price targets, and market insights. Start investing on Public.com.

Trevi Therapeutics recently reported a first‑quarter 2026 net loss of US$13.19 million, broadly flat on a per‑share basis, while outlining plans to advance multiple chronic cough trials for its lead drug Haduvio. Alongside this, the company raised approximately US$162 million in a follow‑on ...